The Experts below are selected from a list of 22773 Experts worldwide ranked by ideXlab platform
Jacques Banchereau - One of the best experts on this subject based on the ideXlab platform.
-
Immunotherapy: Cancer Vaccines on the move.
Nature Reviews Clinical Oncology, 2017Co-Authors: Jacques Banchereau, Karolina PaluckaAbstract:The development of therapeutic Cancer Vaccines has been pursued for many decades. Many Vaccines can elicit immunity to tumour antigens, although their clinical efficacy remains modest. Recent results from two clinical trials highlight the potential of personalized vaccination strategies, made possible by high-throughput approaches to the identification of immunogenic tumour neoantigens. Thus, therapeutic Cancer Vaccines might soon move into the mainstream.
-
dendritic cell based therapeutic Cancer Vaccines
Immunity, 2013Co-Authors: Karolina Palucka, Jacques BanchereauAbstract:The past decade has seen tremendous developments in novel Cancer therapies through the targeting of tumor-cell-intrinsic pathways whose activity is linked to genetic alterations and the targeting of tumor-cell-extrinsic factors, such as growth factors. Furthermore, immunotherapies are entering the clinic at an unprecedented speed after the demonstration that T cells can efficiently reject tumors and that their antitumor activity can be enhanced with antibodies against immune-regulatory molecules (checkpoint blockade). Current immunotherapy strategies include monoclonal antibodies against tumor cells or immune-regulatory molecules, cell-based therapies such as adoptive transfer of ex-vivo-activated T cells and natural killer cells, and Cancer Vaccines. Herein, we discuss the immunological basis for therapeutic Cancer Vaccines and how the current understanding of dendritic cell and T cell biology might enable the development of next-generation curative therapies for individuals with Cancer.
-
recent developments in Cancer Vaccines
Journal of Immunology, 2011Co-Authors: Karolina Palucka, Jacques Banchereau, Hideki UenoAbstract:The adoptive transfer of Cancer Ag-specific effector T cells in patients can result in tumor rejection, thereby illustrating the immune system potential for Cancer therapy. Ideally, one would like to directly induce efficient tumor-specific effector and memory T cells through vaccination. Therapeutic Vaccines have two objectives: priming Ag-specific T cells and reprogramming memory T cells (i.e., a transformation from one type of immunity to another, for example, regulatory to cytotoxic). Recent successful phase III clinical trials showing benefit to the patients revived Cancer Vaccines. Dendritic cells (DCs) are essential in generation of immune responses, and as such represent targets and vectors for vaccination. We have learned that different DC subsets elicit different T cells. Similarly, different activation methods result in DCs able to elicit distinct T cells. We contend that a careful manipulation of activated DCs will allow Cancer immunotherapists to produce the next generation of highly efficient Cancer Vaccines.
Kewal K Jain - One of the best experts on this subject based on the ideXlab platform.
-
Personalized Cancer Vaccines.
Expert Opinion on Biological Therapy, 2010Co-Authors: Kewal K JainAbstract:IMPORTANCE OF THE FIELD: Personalized medicine has extended to management of Cancer and implies prescription of specific therapeutics best suited for an individual patient and the type of tumor. These principles have been applied to Cancer Vaccines. AREAS COVERED IN THIS REVIEW: Various Cancer Vaccines that can be personalized. Tumor-derived Vaccines have been used and active immunotherapy based on antigens specific to the tumor. Dendritic cells (DCs) can prime tumor-specific T cell responses and are considered potentially effective Vaccines for Cancer. DCs may be genetically modified or fused with tumor cells. Adoptive cell therapy is based on autologous antigen-specific T lymphocytes. Personalized peptide vaccination has been combined with chemotherapy. Clinical trials have been conducted. There have been many failures but a selection of those currently in progress is presented. WHAT THE READER WILL GAIN: An overview of various types of personalized Cancer Vaccines, their mechanism of action and current status of development. Causes of failure of clinical trials and concepts of an ideal personalized Cancer vaccine are presented. TAKE HOME MESSAGE: A number of approaches are available for personalized Cancer Vaccines with variable degree of success. There are several challenges and needs for refinement of methods but it remains a promising area of Cancer therapy.
-
Personalized Cancer Vaccines.
Expert opinion on biological therapy, 2010Co-Authors: Kewal K JainAbstract:Importance of the field: Personalized medicine has extended to management of Cancer and implies prescription of specific therapeutics best suited for an individual patient and the type of tumor. These principles have been applied to Cancer Vaccines. Areas covered in this review: Various Cancer Vaccines that can be personalized. Tumor-derived Vaccines have been used and active immunotherapy based on antigens specific to the tumor. Dendritic cells (DCs) can prime tumor-specific T cell responses and are considered potentially effective Vaccines for Cancer. DCs may be genetically modified or fused with tumor cells. Adoptive cell therapy is based on autologous antigen-specific T lymphocytes. Personalized peptide vaccination has been combined with chemotherapy. Clinical trials have been conducted. There have been many failures but a selection of those currently in progress is presented. What the reader will gain: An overview of various types of personalized Cancer Vaccines, their mechanism of action and current...
Karolina Palucka - One of the best experts on this subject based on the ideXlab platform.
-
Immunotherapy: Cancer Vaccines on the move.
Nature Reviews Clinical Oncology, 2017Co-Authors: Jacques Banchereau, Karolina PaluckaAbstract:The development of therapeutic Cancer Vaccines has been pursued for many decades. Many Vaccines can elicit immunity to tumour antigens, although their clinical efficacy remains modest. Recent results from two clinical trials highlight the potential of personalized vaccination strategies, made possible by high-throughput approaches to the identification of immunogenic tumour neoantigens. Thus, therapeutic Cancer Vaccines might soon move into the mainstream.
-
dendritic cell based therapeutic Cancer Vaccines
Immunity, 2013Co-Authors: Karolina Palucka, Jacques BanchereauAbstract:The past decade has seen tremendous developments in novel Cancer therapies through the targeting of tumor-cell-intrinsic pathways whose activity is linked to genetic alterations and the targeting of tumor-cell-extrinsic factors, such as growth factors. Furthermore, immunotherapies are entering the clinic at an unprecedented speed after the demonstration that T cells can efficiently reject tumors and that their antitumor activity can be enhanced with antibodies against immune-regulatory molecules (checkpoint blockade). Current immunotherapy strategies include monoclonal antibodies against tumor cells or immune-regulatory molecules, cell-based therapies such as adoptive transfer of ex-vivo-activated T cells and natural killer cells, and Cancer Vaccines. Herein, we discuss the immunological basis for therapeutic Cancer Vaccines and how the current understanding of dendritic cell and T cell biology might enable the development of next-generation curative therapies for individuals with Cancer.
-
recent developments in Cancer Vaccines
Journal of Immunology, 2011Co-Authors: Karolina Palucka, Jacques Banchereau, Hideki UenoAbstract:The adoptive transfer of Cancer Ag-specific effector T cells in patients can result in tumor rejection, thereby illustrating the immune system potential for Cancer therapy. Ideally, one would like to directly induce efficient tumor-specific effector and memory T cells through vaccination. Therapeutic Vaccines have two objectives: priming Ag-specific T cells and reprogramming memory T cells (i.e., a transformation from one type of immunity to another, for example, regulatory to cytotoxic). Recent successful phase III clinical trials showing benefit to the patients revived Cancer Vaccines. Dendritic cells (DCs) are essential in generation of immune responses, and as such represent targets and vectors for vaccination. We have learned that different DC subsets elicit different T cells. Similarly, different activation methods result in DCs able to elicit distinct T cells. We contend that a careful manipulation of activated DCs will allow Cancer immunotherapists to produce the next generation of highly efficient Cancer Vaccines.
Philip M. Arlen - One of the best experts on this subject based on the ideXlab platform.
-
Therapeutic Prostate Cancer Vaccines: A Review of the Latest Developments
Current opinion in investigational drugs, 2008Co-Authors: Mahsa Mohebtash, James L Gulley, Ravi A. Madan, Philip M. ArlenAbstract:Therapeutic Cancer Vaccines are well-tolerated immunotherapy modalities designed to activate the immune system to kill Cancer cells without a significant effect on normal cells. Better understanding of tumor immunology has led to improved strategies in vaccine development, which have resulted in improved outcomes. This review discusses different types of Cancer Vaccines, focusing predominantly on prostate Cancer Vaccines because of the high prevalence of prostate Cancer and the wide variety of approaches used in prostate Cancer immunotherapy.
-
Cancer Vaccines: Moving Beyond Current Paradigms
Clinical Cancer Research, 2007Co-Authors: Jeffrey Schlom, Philip M. Arlen, James L GulleyAbstract:The field of Cancer Vaccines is currently in an active state of preclinical and clinical investigations. Although no therapeutic Cancer vaccine has to date been approved by the Food and Drug Administration, several new paradigms are emerging from recent clinical findings both in the use of combination therapy approaches and, perhaps more importantly, in clinical trial design and end point analyses. This article will review recent clinical trials involving several different Cancer Vaccines from which data are emerging contrasting classic “tumor response” (Response Evaluation Criteria in Solid Tumors) criteria with “patient response” in the manifestation of increased patient survival post-vaccine therapy. Also described are several strategies in which Cancer Vaccines can be exploited in combination with other agents and therapeutic modalities that are quite unique when compared with “conventional” combination therapies. This is most likely due to the phenomena that ( a ) Cancer Vaccines initiate a dynamic immune process that can be exploited in subsequent therapies and ( b ) both radiation and certain chemotherapeutic agents have been shown to alter the phenotype of tumor cells as to render them more susceptible to T-cell–mediated killing. Consequently, evidence is emerging from several studies in which patient cohorts who first receive a Cancer vaccine (as contrasted with control cohorts) benefit clinically from subsequent therapies.
James L Gulley - One of the best experts on this subject based on the ideXlab platform.
-
Therapeutic Prostate Cancer Vaccines: A Review of the Latest Developments
Current opinion in investigational drugs, 2008Co-Authors: Mahsa Mohebtash, James L Gulley, Ravi A. Madan, Philip M. ArlenAbstract:Therapeutic Cancer Vaccines are well-tolerated immunotherapy modalities designed to activate the immune system to kill Cancer cells without a significant effect on normal cells. Better understanding of tumor immunology has led to improved strategies in vaccine development, which have resulted in improved outcomes. This review discusses different types of Cancer Vaccines, focusing predominantly on prostate Cancer Vaccines because of the high prevalence of prostate Cancer and the wide variety of approaches used in prostate Cancer immunotherapy.
-
Cancer Vaccines: Moving Beyond Current Paradigms
Clinical Cancer Research, 2007Co-Authors: Jeffrey Schlom, Philip M. Arlen, James L GulleyAbstract:The field of Cancer Vaccines is currently in an active state of preclinical and clinical investigations. Although no therapeutic Cancer vaccine has to date been approved by the Food and Drug Administration, several new paradigms are emerging from recent clinical findings both in the use of combination therapy approaches and, perhaps more importantly, in clinical trial design and end point analyses. This article will review recent clinical trials involving several different Cancer Vaccines from which data are emerging contrasting classic “tumor response” (Response Evaluation Criteria in Solid Tumors) criteria with “patient response” in the manifestation of increased patient survival post-vaccine therapy. Also described are several strategies in which Cancer Vaccines can be exploited in combination with other agents and therapeutic modalities that are quite unique when compared with “conventional” combination therapies. This is most likely due to the phenomena that ( a ) Cancer Vaccines initiate a dynamic immune process that can be exploited in subsequent therapies and ( b ) both radiation and certain chemotherapeutic agents have been shown to alter the phenotype of tumor cells as to render them more susceptible to T-cell–mediated killing. Consequently, evidence is emerging from several studies in which patient cohorts who first receive a Cancer vaccine (as contrasted with control cohorts) benefit clinically from subsequent therapies.
